Page last updated: 2024-12-11

oxyfedrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxyfedrine: A drug used in the treatment of angina pectoris, heart failure, conduction defects, and myocardial infarction. It is a partial agonist at beta adrenergic receptors and acts as a coronary vasodilator and cardiotonic agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5489013
CHEMBL ID1651913
CHEBI ID135343
SCHEMBL ID152553
MeSH IDM0015670

Synonyms (40)

Synonym
AC-904
15687-41-9
3-{[(1s,2r)-2-hydroxy-1-methyl-2-phenylethyl]amino}-1-[3-(methyloxy)phenyl]propan-1-one
oxyfedrine
dl-oxyfedrin
dl-3-((beta-hydroxy-alpha-methylphenethyl)amino)-3'-methoxy-propiophenone
1-propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, (r*,s*)-(+-)-
propiophenone, 3-((beta-hydroxy-alpha-methylphenethyl)amino)-3'-methoxy-, stereoisomer
dl-oxyfedrine
oxifedrinum
oxyfedrinum [inn-latin]
oxyfedrine [inn:ban:dcf]
dl-oxyphedrinum
3-(((alphas,betar)-beta-hydroxy-alpha-methylphenethyl)amino)-3'-methoxypropiophenone
oxifedrina [inn-spanish]
1-propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, (r-(r*,s*))-
CHEBI:135343
oxyfedrine (inn)
D08321
3-[[(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-(3-methoxyphenyl)propan-1-one
NCGC00182060-02
CHEMBL1651913
(-)-oxyfedrine
21071-51-2
oxyfedrinum
unii-dwl616xf1k
oxifedrina
dwl616xf1k ,
SCHEMBL152553
3-(((.alpha.s,.beta.r)-.beta.-hydroxy-.alpha.-methylphenethyl)amino)-3'-methoxypropiophenone
oxyfedrine [inn]
1-propanone, 3-(((1s,2r)-2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-
oxyfedrine [who-dd]
oxyfedrine [mi]
DTXSID0023408
AKOS025402433
DB13398
CS-0043279
HY-112070
3-[[(1s,2r)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-(3-methoxyphenyl)-1-propanone;

Research Excerpts

Actions

Oxyfedrine does not produce a further increase in the heat conductance values after previous application of digoxin. When measuring the blood flow with labelled microspheres the same result was found.

ExcerptReferenceRelevance
"Oxyfedrine does not produce a further increase in the heat conductance values after previous application of digoxin; when measuring the blood flow with labelled microspheres the same result was found, which means that by previous administration of digoxin the circulatory effect of oxyfedrine is obviously inhibited."( [The action of oxyfedrine on haemodynamics, inotropism and blood perfusion of the partially ischaemic myocardium after digoxin premedication. Studies on anaesthetized dogs (author's transl)].
Felix, R; Hahn, N; Henn, I; Holst, A; Malotki, D; Oehr, P; Raqué, B; von Randow, H, 1981
)
1.34
"Oxyfedrine did not increase the total duration of exercise (4.1 +/- 1.0 to 4.7 +/- 2.2 minutes, p = NS) or time to ischaemic symptoms (2.7 +/- 1.3 to 2.9 +/- 1.9 minutes, p = NS)."( Effect of intravenous oxyfedrine on exercise in patients with ischaemic heart disease.
Alexander, T; Krishnaswami, S,
)
1.17

Pharmacokinetics

ExcerptReferenceRelevance
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
"The pharmacokinetics and comparative bioavailability of oxyfedrine after single-dose oral administration of oxyfedrine*HCl tablets in comparison to an equimolar aqueous solution of oxyfedrine*HCl were investigated in 12 healthy male subjects."( Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions.
Birkel, M; Fuder, H; Lücker, PW; Scheithauer, S; Stiegler, S; Thümmler, D; Wetzelsberger, N, 1995
)
0.82

Dosage Studied

ExcerptRelevanceReference
" In a dosage of 300 mg a day orally trapymin had no clear influence on the non-esterified fatty acids."( [Influence of coronary-effective substances on the concentration of nonesterified fatty acids in the serum of patients with angina pectoris].
Heiland, G; Modersohn, D; Pankau, H; Urbaszek, W, 1975
)
0.25
" Thus, the dose-dependent hemodynamic effects of isoprenaline were significantly attenuated by oxyfedrine pre-treatment with a shift of the dose-response curve to the right; this was attributed to a beta-antagonistic property of oxyfedrine."( [Mechanism of action of oxyfedrine as a partial beta receptor agonist].
Bette, L; Rettig, G; Schieffer, H; Sternitzke, N, 1984
)
0.79
" Relevant concentrations of the parent drug were found only in the high dosage group."( Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions.
Birkel, M; Fuder, H; Lücker, PW; Scheithauer, S; Stiegler, S; Thümmler, D; Wetzelsberger, N, 1995
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (137)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990117 (85.40)18.7374
1990's12 (8.76)18.2507
2000's4 (2.92)29.6817
2010's3 (2.19)24.3611
2020's1 (0.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.05 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index4.07 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (17.42%)5.53%
Reviews7 (4.52%)6.00%
Case Studies2 (1.29%)4.05%
Observational0 (0.00%)0.25%
Other119 (76.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]